Kailera Therapeutics priced a $625 million initial public offering, marking one of the largest biotech IPOs on record and positioning the company to fund its obesity pipeline. The offering capital is intended to support advancement of obesity therapeutics licensed from China’s Hengrui Pharma. The debut follows a period of renewed capital access for obesity-focused developers, with investors increasingly rewarding differentiated metabolic mechanisms. Kailera’s fundraise also sets a benchmark for first-time public companies targeting metabolic disease. With proceeds earmarked for clinical and platform work, Kailera is now set up to compete on both next-generation efficacy and tolerability as the GLP-1-dominant obesity market expands.